Overview

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Status:
Active, not recruiting

Trial end date:
2022-06-07

Target enrollment:

Participant gender:

Summary

This phase II trial studies olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places in the body (advanced or metastatic) or cannot be removed by surgery (unresectable). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and temozolomide may work better than giving either drug alone in treating patients with LMS.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Temozolomide